StockUS listing USDSKYFPINKHealthcareQuality Compounder

Daiichi Sankyo Company Limited(DSKYF) Stock Analysis | Healthcare

USD --+0.00%
Reward71High
Risk22Low
75%Data
2.9% dividend yield · Revenue growing 15% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 35.36Bn
Reward Ratingⓘ71 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ22 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DSKYF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Daiichi Sankyo Company Limited?

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.

AI Brief Pro

The brief on Daiichi Sankyo Company Limited

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Daiichi Sankyo Company Limited?

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat adult patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 35.36B, and a P/E ratio of 19.7x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (71)

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
P/E Ratio19.6907
Beta-0.326
Insider Activity
12M windowNo data
No insider activity data available for this ticker.